SCHEMBL1372278

SCHEMBL1372278

OCC(O)COC(F)(F)CF

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27902633 0.78 LMNA (0.40) ALDH1A1LMNAUSP2
SCHEMBL5350631 0.71 USP2 (0.51) LMNAUSP2
SCHEMBL13447526 0.71 USP2 (0.34) ALDH1A1LMNAUSP2
SCHEMBL27561102 0.70 LMNA (0.42) ALDH1A1LMNAUSP2
SCHEMBL9227304 0.70
SCHEMBL5349184 0.70 ALDH1A1 (0.32) ALDH1A1LMNA
SCHEMBL28401193 0.70 USP2 (0.37) ALDH1A1LMNAUSP2
SCHEMBL5349194 0.70 ALDH1A1 (0.32) ALDH1A1LMNA
SCHEMBL6269634 0.69 LMNA (0.40) ALDH1A1LMNAUSP2
SCHEMBL116799 0.69 MAPK1 (0.56) ALDH1A1LMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022999-A1 PROTEIN FRAGMENT COMPLEMENTATION ASSAYS FOR THE DETECTION OF BIOLOGICAL OR DRUG INTERACTIONS ODYSSEY PHARMACEUTICALS, INC. (US) 2013-01-24 US disclosed
US-8192944-B2 Protein fragment complementation assays for the detection of biological or drug interactions ODYSSEY THERA INC. (US) 2012-06-05 US disclosed
US-20110287950-A1 Protein fragment complementation assays for the detection of biological or drug interactions ODYSSEY PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed
US-7989218-B2 Protein fragment complementation assays for the detection of biological or drug interactions ODYSSEY THERA INC. (US) 2011-08-02 US disclosed
US-20080145315-A1 Protein fragment complementation assays in whole animals applications to drug efficacy, adme, cancer biology, immunology, infectious disease and gene therapy ODYSSEY PHARMACEUTICALS, INC. (US) 2008-06-19 US disclosed
US-7306914-B2 Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy ODYSSEY THERA INC. (US) 2007-12-11 US disclosed
US-20070148682-A1 Protein fragment complementation assays for the detection of biological or drug interactions ODYSSEY PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
US-7160691-B2 Protein fragment complementation assays for the detection of biological or drug interactions ODYSSEY THERA INC. (US) 2007-01-09 US disclosed
US-6929916-B2 Protein fragment complementation assays for the detection of biological or drug interactions ODYSSEY THERA INC. (US) 2005-08-16 US disclosed
US-20050079547-A1 Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy MICHNICK STEPHEN WILLIAM WATSO (CA) 2005-04-14 US disclosed
US-6294330-B1 SCREENING LIGANDS OF CELLULAR RECEPTOR BY GENERATING VECTORS ENCODING FUSION PROTEINS OF FRAGMENTS OF REPORTER MOLECULE AND SUBDOMAINS OF RECEPTOR, TRANSFECTING CELLS WITH VECTORS, TESTING CELLS FOR REPORTER MOLECULE ACTIVITY ODYSSEY PHARMACEUTICALS INC. 2001-09-25 US disclosed
US-6270964-B1 POLYPEPTIDE USED A DIAGNOSTIC TOOL IN GENETIC ENGINEERING ODYSSEY PHARMACEUTICALS INC. 2001-08-07 US disclosed